Successful salvage therapy with micafungin for Candida empyema thoracis
Pai-Yang Lin, Shio-Shin Jean, Tsong-Yih Ou, Fu-Lun Chen, Wen-Sen Lee
Received: December 12, 2013 Revised: December 30, 2013 Accepted: December 30, 2013
Corresponding author. Division of Infectious Diseases, Department of Internal Medicine, Wan Fang Medical Center, Taipei Medical University, Number 111, Section 3, Hsing-Lung Road, Taipei 116, Taiwan.
Background and purpose:
We read with great interest the article by Lin et al1 in the Journal of Microbiology, Immunology and Infection in which they reported that Candida empyema thoracis is a serious complication of invasive candidiasis and has a high mortality. The success rate of fluconazole treatment remains uncertain. Candida albicans is the most common etiology of fungal empyema thoracis. However, the golden standard treatment for it is controversial. In this paper, we report a patient who was diagnosed as having nosocomial Candida empyema thoracis with acute respiratory failure.